Equity Overview
Price & Market Data
Price: $6.91
Daily Change: -$0.46 / 6.66%
Daily Range: $6.75 - $7.85
Market Cap: $4,064,234
Daily Volume: 6,266
Performance Metrics
1 Week: 3.13%
1 Month: -26.10%
3 Months: 12.64%
6 Months: -36.52%
1 Year: -64.74%
YTD: -69.66%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.